Gemcitabine confirmed as the first-line therapy for pancreatic cancer

被引：3
|
作者：
Claire Greenhill
机构：
来源：
Nature Reviews Gastroenterology & Hepatology | 2011年 / 8卷 / 1期
关键词：
D O I：
10.1038/nrgastro.2010.200
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3 / 3
相关论文
共 50 条
  • [31] Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial
    Blackstein, M
    Vogel, CL
    Ambinder, R
    Cowan, J
    Iglesias, J
    Melemed, A
    ONCOLOGY, 2002, 62 (01) : 2 - 8
  • [32] Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma
    Yoshiyuki Yamagishi
    Hajime Higuchi
    Motoko Izumiya
    Gen Sakai
    Hideko Iizuka
    Shoko Nakamura
    Masayuki Adachi
    Sigenari Hozawa
    Hiromasa Takaishi
    Toshifumi Hibi
    Journal of Gastroenterology, 2010, 45 : 1146 - 1154
  • [33] Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma
    Yamagishi, Yoshiyuki
    Higuchi, Hajime
    Izumiya, Motoko
    Sakai, Gen
    Iizuka, Hideko
    Nakamura, Shoko
    Adachi, Masayuki
    Hozawa, Sigenari
    Takaishi, Hiromasa
    Hibi, Toshifumi
    JOURNAL OF GASTROENTEROLOGY, 2010, 45 (11) : 1146 - 1154
  • [34] Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study
    Guo, Jhe-Cyuan
    Yang, Shih-Hung
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (04) : 634 - 642
  • [35] Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study
    Jhe-Cyuan Guo
    Shih-Hung Yang
    International Journal of Clinical Oncology, 2014, 19 : 634 - 642
  • [36] Outcomes of gemcitabine (Gem)-based palliative first-line therapy in the treatment of recurrent disease or of initially unresectable pancreatic cancer (PC).
    Rosenblender, Sina
    Stieler, Jens
    Bischoff, Sven
    Sinn, Marianne
    Pelzer, Uwe
    Striefler, Jana Kaethe
    Doerken, Bernd
    Riess, Hanno
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Clinicogenomic determinants of response to FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first-line systemic therapy for pancreatic cancer
    Tong, Kunling
    Kanu, Elishama
    Agritelley, Ethan
    Bao, Jiayin
    Allen, Peter J.
    Nussbaum, Daniel P.
    CANCER RESEARCH, 2024, 84 (17)
  • [38] Class III β-Tubulin Expression Is of Value in Selecting nab-Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer
    Kato, Akihisa
    Naitoh, Itaru
    Naiki-Ito, Aya
    Hayashi, Kazuki
    Okumura, Fumihiro
    Fujita, Yasuaki
    Sano, Hitoshi
    Nishi, Yuji
    Miyabe, Katsuyuki
    Inoue, Tadahisa
    Hirano, Atsuyuki
    Takada, Hiroki
    Yoshida, Michihiro
    Hori, Yasuki
    Natsume, Makoto
    Kato, Hiroyuki
    Takahashi, Satoru
    Kataoka, Hiromi
    PANCREAS, 2022, 51 (04) : 372 - 379
  • [39] First-Line Treatment for Advanced Pancreatic Cancer
    Oberstein, Paul E.
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2011, 12 (02): : 96 - 100
  • [40] First-Line Treatment of Metastatic Pancreatic Cancer
    Tokh, Mohammed
    Bathini, Venu
    Saif, Muhammad Wasif
    JOURNAL OF THE PANCREAS, 2012, 13 (02): : 159 - 162
12345